Survey of malignant pleural mesothelioma treatment in Japan: Patterns of practice and clinical outcomes in tomotherapy facilities

J Radiat Res. 2022 Mar 17;63(2):281-289. doi: 10.1093/jrr/rrab127.

Abstract

We conducted a nationwide survey of tomotherapy for malignant pleural mesothelioma (MPM) in Japan. Fifty-six facilities were surveyed and data on 31 patients treated curatively between 2008 and 2017 were collected from 14 facilities. Twenty patients received hemithorax irradiation after extrapleural pneumonectomy (EPP) (first group). Five patients received irradiation without EPP (second group), while six received salvage radiotherapy for local recurrence (salvage group). Among the seven patients not undergoing EPP, five (four in the second group and one in the salvage group) were treated with lung sparing pleural irradiation (LSPI) and two with irradiation to visible tumors. Two-year overall survival (OS) rates in the first and second groups were 33% and 60%, respectively (median, 13 vs 30 months, P = 0.82). In the first and second groups, 2-year local control (LC) rates were 53 and 67%, respectively (P = 0.54) and 2-year progression-free survival (PFS) rates were 16% and 60%, respectively (P = 0.07). Distant metastases occurred in 15 patients in the first group and three in the second group. In the salvage group, the median OS was 18 months. Recurrence was observed in the irradiated volume in four patients. The contralateral lung dose was higher in LSPI than in hemithorax irradiation plans (mean, 11.0 ± 2.2 vs 6.1 ± 3.1 Gy, P = 0.002). Grade 3 or 5 lung toxicity was observed in two patients receiving EPP and hemithorax irradiation, but not in those undergoing LSPI. In conclusion, outcomes of EPP and hemithorax irradiation were not satisfactory, whereas LSPI appeared promising and encouraging.

Keywords: hyperthermia; intensity-modulated radiotherapy (IMRT); lung sparing pleural irradiation (LSPI); malignant pleural mesothelioma (MPM); nationwide survey in Japan; tomotherapy; whole hemithorax irradiation (WHI).

MeSH terms

  • Combined Modality Therapy
  • Humans
  • Japan
  • Lung Neoplasms* / pathology
  • Mesothelioma* / pathology
  • Mesothelioma* / radiotherapy
  • Mesothelioma, Malignant* / radiotherapy
  • Pleural Neoplasms* / pathology
  • Pleural Neoplasms* / radiotherapy
  • Pneumonectomy / adverse effects
  • Radiotherapy, Intensity-Modulated* / adverse effects
  • Treatment Outcome